Anthony P. Bihl, Director of Meridian Bioscience Inc. (NASDAQ: VIVO) recently purchased approximately 5000 shares of VIVO stocks. The transaction was made on 25th November, Wednesday. Anthony Bihl reportedly bought the shares at $17.65 PS of average price leading to the total of $88,250.00. After this massive transaction, VIVO’s Director currently owns a total of 10,851 shares that can be valued at roughly $191,520.15.
VIVO Stock Analysis Following Director’s Purchase
NASDAQ: VIVO stocks traded at $18.57 this Friday. According to recent stats, the quick ratio of VFC stocks is 2.61. 4.00 is the company’s current ratio. The debt-to-equity ratio stands at 0.42. VIVO’s market cap is $807.24 million. The PE ratio stands at 18.19. The beta value of the company’s stocks is 0.60. The 12-monthly low for NASDAQ: VIVO stock is $5.51 and the high is $26.58. The 50-day simple moving average (50SMA) is valued at $18.17 and the 200SMA is that of $18.40.
The quarterly earnings report was last released on the 18th of November. The earnings stood at $0.19 EPS. This was opposed to the consensus of $0.14. So, NASDAQ: VIVO beat the consensus by $0.05.
The company’s return on equity also stood at 21.11% along with the net margin of 18.22%. The expected revenue for the firm was marked at $59.47 million but it made $64.15 million. Expert analysts forecast that VIVO stocks will post an EPS of $1.02 for FY2020.
Several institutional investors have increased their holdings in VIVO stocks recently. The company was rated “sell” by one analyst, “buy” by four analysts, “strong buy” by one. Thus, the recent consensus regarding VIVO stocks stands at a “Buy” rating with $21.92 as a consensus on the target price. Several hedge funds have also been involved in buying and selling of NASDAQ: VIVO shares recently.
